Peter J Weiden

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 6

Top Topics

Bipolar Disorder

Top Venues

Patient preference and adherence

Schizophrenia (Heidelberg, Germany)

Neuropsychiatric disease and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Christoph U Correll, Angel S Angelov, Andrew C Miller, Peter J Weiden, Stephen K Brannan
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia (Heidelberg, Germany) 8 (1) (2022)
Michael J Doane, Martha Sajatovic, Peter J Weiden, Amy K O'Sullivan, Stephen Maher, Jakob Bue Bjorner, Asia Sikora Kessler, Julia Carpenter-Conlin, Leona Bessonova, Dawn I Velligan
Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey. Patient preference and adherence 14 (2020)
Rakesh Jain, Jonathan Meyer, Angela Wehr, Bhaskar Rege, Lisa von Moltke, Peter J Weiden
Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS spectrums 25 (3) (2019)
Citrome Leslie, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell, Peter J Weiden
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric disease and treatment 15 (2019)
Peter J Weiden, Yangchun Du, Chih-Chin Liu, Arielle D Stanford
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS spectrums 24 (4) (2018)
Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weiden
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums 24 (4) (2018)